Cargando…

Effects of galactooligosaccharides on maternal gut microbiota, glucose metabolism, lipid metabolism and inflammation in pregnancy: A randomized controlled pilot study

BACKGROUND: Gut microbiota of pregnant women change with the gestational week. On the one hand, they participate in the metabolic adaptation of pregnant women. On the other hand, the abnormal composition of gut microbiota of pregnant women is more likely to suffer from gestational diabetes mellitus...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Jiayang, An, Lin, Ren, Zhenghong, Wang, Shuxian, Yang, Huixia, Ma, Jingmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911812/
https://www.ncbi.nlm.nih.gov/pubmed/36777355
http://dx.doi.org/10.3389/fendo.2023.1034266
_version_ 1784885073126883328
author Wan, Jiayang
An, Lin
Ren, Zhenghong
Wang, Shuxian
Yang, Huixia
Ma, Jingmei
author_facet Wan, Jiayang
An, Lin
Ren, Zhenghong
Wang, Shuxian
Yang, Huixia
Ma, Jingmei
author_sort Wan, Jiayang
collection PubMed
description BACKGROUND: Gut microbiota of pregnant women change with the gestational week. On the one hand, they participate in the metabolic adaptation of pregnant women. On the other hand, the abnormal composition of gut microbiota of pregnant women is more likely to suffer from gestational diabetes mellitus (GDM). Therefore, gut microbiota targeted treatment through dietary supplements is particularly important for prevention or treatment. Prebiotic supplements containing galactooligosaccharides (GOS) may be an intervention method, but the effect is still unclear. OBJECTIVE: This study aims to evaluate the feasibility and acceptability of prebiotic intervention in healthy pregnant women during pregnancy, and to explore the possible effects of intervention on pregnant women and the influence on gut microbiota as preliminaries. METHODS: After recruitment in first trimester, 52 pregnant women were randomly assigned to receive GOS intervention or placebo containing fructooligosaccharides. 16S rRNA sequencing technology was used to detect the composition, diversity and differential flora of gut microbiota. Lipid metabolism, glucose metabolism and inflammatory factors during pregnancy were also analyzed. RESULTS: The adverse symptoms of GOS intervention are mild and relatively safe. For pregnant women, there was no significant difference in the GDM incidence rates and gestational weight gain (GWG) in the GOS group compared with placebo (P > 0.05). Compared with the placebo group, the levels of FPG, TG, TC, HDL-C LDL-C, and IL-6 had no significant difference in GOS group (P > 0.05). For newborns, there was no significant difference between GOS group and placebo group in the following variables including gestational week, birth weight, birth length, head circumference, chest circumference, sex, and delivery mode (P > 0.05). And compared with the placebo group, the GOS group had a higher abundance of Paraprevotella and Dorea, but lower abundance of LachnospiraceaeUCG_001. CONCLUSIONS: GOS prebiotics appear to be safe and acceptable for the enrolled pregnancies. Although GOS intervention did not show the robust benefits on glucose and lipid metabolism. However, the intervention had a certain impact on the compostion of gut microbiota. GOS can be considered as a dietary supplement during pregnancy, and further clinical studies are needed to explore this in the future.
format Online
Article
Text
id pubmed-9911812
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99118122023-02-11 Effects of galactooligosaccharides on maternal gut microbiota, glucose metabolism, lipid metabolism and inflammation in pregnancy: A randomized controlled pilot study Wan, Jiayang An, Lin Ren, Zhenghong Wang, Shuxian Yang, Huixia Ma, Jingmei Front Endocrinol (Lausanne) Endocrinology BACKGROUND: Gut microbiota of pregnant women change with the gestational week. On the one hand, they participate in the metabolic adaptation of pregnant women. On the other hand, the abnormal composition of gut microbiota of pregnant women is more likely to suffer from gestational diabetes mellitus (GDM). Therefore, gut microbiota targeted treatment through dietary supplements is particularly important for prevention or treatment. Prebiotic supplements containing galactooligosaccharides (GOS) may be an intervention method, but the effect is still unclear. OBJECTIVE: This study aims to evaluate the feasibility and acceptability of prebiotic intervention in healthy pregnant women during pregnancy, and to explore the possible effects of intervention on pregnant women and the influence on gut microbiota as preliminaries. METHODS: After recruitment in first trimester, 52 pregnant women were randomly assigned to receive GOS intervention or placebo containing fructooligosaccharides. 16S rRNA sequencing technology was used to detect the composition, diversity and differential flora of gut microbiota. Lipid metabolism, glucose metabolism and inflammatory factors during pregnancy were also analyzed. RESULTS: The adverse symptoms of GOS intervention are mild and relatively safe. For pregnant women, there was no significant difference in the GDM incidence rates and gestational weight gain (GWG) in the GOS group compared with placebo (P > 0.05). Compared with the placebo group, the levels of FPG, TG, TC, HDL-C LDL-C, and IL-6 had no significant difference in GOS group (P > 0.05). For newborns, there was no significant difference between GOS group and placebo group in the following variables including gestational week, birth weight, birth length, head circumference, chest circumference, sex, and delivery mode (P > 0.05). And compared with the placebo group, the GOS group had a higher abundance of Paraprevotella and Dorea, but lower abundance of LachnospiraceaeUCG_001. CONCLUSIONS: GOS prebiotics appear to be safe and acceptable for the enrolled pregnancies. Although GOS intervention did not show the robust benefits on glucose and lipid metabolism. However, the intervention had a certain impact on the compostion of gut microbiota. GOS can be considered as a dietary supplement during pregnancy, and further clinical studies are needed to explore this in the future. Frontiers Media S.A. 2023-01-27 /pmc/articles/PMC9911812/ /pubmed/36777355 http://dx.doi.org/10.3389/fendo.2023.1034266 Text en Copyright © 2023 Wan, An, Ren, Wang, Yang and Ma https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Wan, Jiayang
An, Lin
Ren, Zhenghong
Wang, Shuxian
Yang, Huixia
Ma, Jingmei
Effects of galactooligosaccharides on maternal gut microbiota, glucose metabolism, lipid metabolism and inflammation in pregnancy: A randomized controlled pilot study
title Effects of galactooligosaccharides on maternal gut microbiota, glucose metabolism, lipid metabolism and inflammation in pregnancy: A randomized controlled pilot study
title_full Effects of galactooligosaccharides on maternal gut microbiota, glucose metabolism, lipid metabolism and inflammation in pregnancy: A randomized controlled pilot study
title_fullStr Effects of galactooligosaccharides on maternal gut microbiota, glucose metabolism, lipid metabolism and inflammation in pregnancy: A randomized controlled pilot study
title_full_unstemmed Effects of galactooligosaccharides on maternal gut microbiota, glucose metabolism, lipid metabolism and inflammation in pregnancy: A randomized controlled pilot study
title_short Effects of galactooligosaccharides on maternal gut microbiota, glucose metabolism, lipid metabolism and inflammation in pregnancy: A randomized controlled pilot study
title_sort effects of galactooligosaccharides on maternal gut microbiota, glucose metabolism, lipid metabolism and inflammation in pregnancy: a randomized controlled pilot study
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911812/
https://www.ncbi.nlm.nih.gov/pubmed/36777355
http://dx.doi.org/10.3389/fendo.2023.1034266
work_keys_str_mv AT wanjiayang effectsofgalactooligosaccharidesonmaternalgutmicrobiotaglucosemetabolismlipidmetabolismandinflammationinpregnancyarandomizedcontrolledpilotstudy
AT anlin effectsofgalactooligosaccharidesonmaternalgutmicrobiotaglucosemetabolismlipidmetabolismandinflammationinpregnancyarandomizedcontrolledpilotstudy
AT renzhenghong effectsofgalactooligosaccharidesonmaternalgutmicrobiotaglucosemetabolismlipidmetabolismandinflammationinpregnancyarandomizedcontrolledpilotstudy
AT wangshuxian effectsofgalactooligosaccharidesonmaternalgutmicrobiotaglucosemetabolismlipidmetabolismandinflammationinpregnancyarandomizedcontrolledpilotstudy
AT yanghuixia effectsofgalactooligosaccharidesonmaternalgutmicrobiotaglucosemetabolismlipidmetabolismandinflammationinpregnancyarandomizedcontrolledpilotstudy
AT majingmei effectsofgalactooligosaccharidesonmaternalgutmicrobiotaglucosemetabolismlipidmetabolismandinflammationinpregnancyarandomizedcontrolledpilotstudy